Financhill
Buy
58

INCY Quote, Financials, Valuation and Earnings

Last price:
$72.13
Seasonality move :
-3.94%
Day range:
$71.50 - $72.97
52-week range:
$50.35 - $83.95
Dividend yield:
0%
P/E ratio:
267.15x
P/S ratio:
3.61x
P/B ratio:
4.05x
Volume:
1.3M
Avg. volume:
1.6M
1-year change:
19.56%
Market cap:
$14B
Revenue:
$4.2B
EPS (TTM):
$0.27

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
INCY
Incyte
$1.1B $1.55 14.09% 40.38% $78.26
BMRN
Biomarin Pharmaceutical
$711M $0.74 14.07% 115.22% $96.71
BPMC
Blueprint Medicines
$145.2M -$0.71 66.77% -60.76% $126.79
EXEL
Exelixis
$563.2M $0.49 16.5% 248.48% $36.89
HALO
Halozyme Therapeutics
$285.7M $1.16 17.06% 57.62% $66.11
SNDX
Syndax Pharmaceuticals
$86.3M -$0.26 -- -74.42% $36.23
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
INCY
Incyte
$72.13 $78.26 $14B 267.15x $0.00 0% 3.61x
BMRN
Biomarin Pharmaceutical
$68.28 $96.71 $13B 31.04x $0.00 0% 4.75x
BPMC
Blueprint Medicines
$92.25 $126.79 $5.9B -- $0.00 0% 11.50x
EXEL
Exelixis
$36.85 $36.89 $10.3B 20.82x $0.00 0% 5.03x
HALO
Halozyme Therapeutics
$57.72 $66.11 $7.1B 16.83x $0.00 0% 7.35x
SNDX
Syndax Pharmaceuticals
$16.38 $36.23 $1.4B -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
INCY
Incyte
-- 0.833 -- 1.83x
BMRN
Biomarin Pharmaceutical
9.52% 0.496 4.75% 2.96x
BPMC
Blueprint Medicines
56.44% 2.337 6.96% 2.66x
EXEL
Exelixis
-- -0.022 -- 3.41x
HALO
Halozyme Therapeutics
80.54% 2.008 25.58% 6.50x
SNDX
Syndax Pharmaceuticals
-- 1.421 -- 6.92x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
INCY
Incyte
$1.1B $297.4M 0.81% 0.81% 26.65% $363.8M
BMRN
Biomarin Pharmaceutical
$611.2M $161.4M 6.92% 8.09% 23.05% $165.3M
BPMC
Blueprint Medicines
$138.9M -$41.2M -11.14% -24.43% -21.26% -$30.3M
EXEL
Exelixis
$546.8M $163.5M 23.63% 23.63% 28.84% $226.3M
HALO
Halozyme Therapeutics
$256M $175.5M 25.01% 162.37% 61.33% $175.4M
SNDX
Syndax Pharmaceuticals
-- -$89.6M -67.33% -67.33% -672.82% -$62.3M

Incyte vs. Competitors

  • Which has Higher Returns INCY or BMRN?

    Biomarin Pharmaceutical has a net margin of 17.07% compared to Incyte's net margin of 16.72%. Incyte's return on equity of 0.81% beat Biomarin Pharmaceutical's return on equity of 8.09%.

    Company Gross Margin Earnings Per Share Invested Capital
    INCY
    Incyte
    92.49% $1.02 $3.4B
    BMRN
    Biomarin Pharmaceutical
    81.78% $0.64 $6.3B
  • What do Analysts Say About INCY or BMRN?

    Incyte has a consensus price target of $78.26, signalling upside risk potential of 8.49%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $96.71 which suggests that it could grow by 41.64%. Given that Biomarin Pharmaceutical has higher upside potential than Incyte, analysts believe Biomarin Pharmaceutical is more attractive than Incyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    INCY
    Incyte
    10 15 0
    BMRN
    Biomarin Pharmaceutical
    15 7 0
  • Is INCY or BMRN More Risky?

    Incyte has a beta of 0.699, which suggesting that the stock is 30.125% less volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.285, suggesting its less volatile than the S&P 500 by 71.55%.

  • Which is a Better Dividend Stock INCY or BMRN?

    Incyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Incyte pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios INCY or BMRN?

    Incyte quarterly revenues are $1.2B, which are larger than Biomarin Pharmaceutical quarterly revenues of $747.3M. Incyte's net income of $201.2M is higher than Biomarin Pharmaceutical's net income of $124.9M. Notably, Incyte's price-to-earnings ratio is 267.15x while Biomarin Pharmaceutical's PE ratio is 31.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte is 3.61x versus 4.75x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    INCY
    Incyte
    3.61x 267.15x $1.2B $201.2M
    BMRN
    Biomarin Pharmaceutical
    4.75x 31.04x $747.3M $124.9M
  • Which has Higher Returns INCY or BPMC?

    Blueprint Medicines has a net margin of 17.07% compared to Incyte's net margin of -34.13%. Incyte's return on equity of 0.81% beat Blueprint Medicines's return on equity of -24.43%.

    Company Gross Margin Earnings Per Share Invested Capital
    INCY
    Incyte
    92.49% $1.02 $3.4B
    BPMC
    Blueprint Medicines
    94.91% -$0.79 $685.6M
  • What do Analysts Say About INCY or BPMC?

    Incyte has a consensus price target of $78.26, signalling upside risk potential of 8.49%. On the other hand Blueprint Medicines has an analysts' consensus of $126.79 which suggests that it could grow by 37.44%. Given that Blueprint Medicines has higher upside potential than Incyte, analysts believe Blueprint Medicines is more attractive than Incyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    INCY
    Incyte
    10 15 0
    BPMC
    Blueprint Medicines
    9 5 1
  • Is INCY or BPMC More Risky?

    Incyte has a beta of 0.699, which suggesting that the stock is 30.125% less volatile than S&P 500. In comparison Blueprint Medicines has a beta of 0.616, suggesting its less volatile than the S&P 500 by 38.367%.

  • Which is a Better Dividend Stock INCY or BPMC?

    Incyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Blueprint Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Incyte pays -- of its earnings as a dividend. Blueprint Medicines pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios INCY or BPMC?

    Incyte quarterly revenues are $1.2B, which are larger than Blueprint Medicines quarterly revenues of $146.4M. Incyte's net income of $201.2M is higher than Blueprint Medicines's net income of -$50M. Notably, Incyte's price-to-earnings ratio is 267.15x while Blueprint Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte is 3.61x versus 11.50x for Blueprint Medicines. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    INCY
    Incyte
    3.61x 267.15x $1.2B $201.2M
    BPMC
    Blueprint Medicines
    11.50x -- $146.4M -$50M
  • Which has Higher Returns INCY or EXEL?

    Exelixis has a net margin of 17.07% compared to Incyte's net margin of 24.68%. Incyte's return on equity of 0.81% beat Exelixis's return on equity of 23.63%.

    Company Gross Margin Earnings Per Share Invested Capital
    INCY
    Incyte
    92.49% $1.02 $3.4B
    EXEL
    Exelixis
    96.48% $0.48 $2.2B
  • What do Analysts Say About INCY or EXEL?

    Incyte has a consensus price target of $78.26, signalling upside risk potential of 8.49%. On the other hand Exelixis has an analysts' consensus of $36.89 which suggests that it could grow by 0.1%. Given that Incyte has higher upside potential than Exelixis, analysts believe Incyte is more attractive than Exelixis.

    Company Buy Ratings Hold Ratings Sell Ratings
    INCY
    Incyte
    10 15 0
    EXEL
    Exelixis
    8 9 0
  • Is INCY or EXEL More Risky?

    Incyte has a beta of 0.699, which suggesting that the stock is 30.125% less volatile than S&P 500. In comparison Exelixis has a beta of 0.529, suggesting its less volatile than the S&P 500 by 47.112%.

  • Which is a Better Dividend Stock INCY or EXEL?

    Incyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exelixis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Incyte pays -- of its earnings as a dividend. Exelixis pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios INCY or EXEL?

    Incyte quarterly revenues are $1.2B, which are larger than Exelixis quarterly revenues of $566.8M. Incyte's net income of $201.2M is higher than Exelixis's net income of $139.9M. Notably, Incyte's price-to-earnings ratio is 267.15x while Exelixis's PE ratio is 20.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte is 3.61x versus 5.03x for Exelixis. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    INCY
    Incyte
    3.61x 267.15x $1.2B $201.2M
    EXEL
    Exelixis
    5.03x 20.82x $566.8M $139.9M
  • Which has Higher Returns INCY or HALO?

    Halozyme Therapeutics has a net margin of 17.07% compared to Incyte's net margin of 45.98%. Incyte's return on equity of 0.81% beat Halozyme Therapeutics's return on equity of 162.37%.

    Company Gross Margin Earnings Per Share Invested Capital
    INCY
    Incyte
    92.49% $1.02 $3.4B
    HALO
    Halozyme Therapeutics
    85.89% $1.06 $1.9B
  • What do Analysts Say About INCY or HALO?

    Incyte has a consensus price target of $78.26, signalling upside risk potential of 8.49%. On the other hand Halozyme Therapeutics has an analysts' consensus of $66.11 which suggests that it could grow by 14.54%. Given that Halozyme Therapeutics has higher upside potential than Incyte, analysts believe Halozyme Therapeutics is more attractive than Incyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    INCY
    Incyte
    10 15 0
    HALO
    Halozyme Therapeutics
    3 4 0
  • Is INCY or HALO More Risky?

    Incyte has a beta of 0.699, which suggesting that the stock is 30.125% less volatile than S&P 500. In comparison Halozyme Therapeutics has a beta of 1.254, suggesting its more volatile than the S&P 500 by 25.393%.

  • Which is a Better Dividend Stock INCY or HALO?

    Incyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Halozyme Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Incyte pays -- of its earnings as a dividend. Halozyme Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios INCY or HALO?

    Incyte quarterly revenues are $1.2B, which are larger than Halozyme Therapeutics quarterly revenues of $298M. Incyte's net income of $201.2M is higher than Halozyme Therapeutics's net income of $137M. Notably, Incyte's price-to-earnings ratio is 267.15x while Halozyme Therapeutics's PE ratio is 16.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte is 3.61x versus 7.35x for Halozyme Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    INCY
    Incyte
    3.61x 267.15x $1.2B $201.2M
    HALO
    Halozyme Therapeutics
    7.35x 16.83x $298M $137M
  • Which has Higher Returns INCY or SNDX?

    Syndax Pharmaceuticals has a net margin of 17.07% compared to Incyte's net margin of -673.01%. Incyte's return on equity of 0.81% beat Syndax Pharmaceuticals's return on equity of -67.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    INCY
    Incyte
    92.49% $1.02 $3.4B
    SNDX
    Syndax Pharmaceuticals
    -- -$0.98 $366.4M
  • What do Analysts Say About INCY or SNDX?

    Incyte has a consensus price target of $78.26, signalling upside risk potential of 8.49%. On the other hand Syndax Pharmaceuticals has an analysts' consensus of $36.23 which suggests that it could grow by 121.19%. Given that Syndax Pharmaceuticals has higher upside potential than Incyte, analysts believe Syndax Pharmaceuticals is more attractive than Incyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    INCY
    Incyte
    10 15 0
    SNDX
    Syndax Pharmaceuticals
    10 1 0
  • Is INCY or SNDX More Risky?

    Incyte has a beta of 0.699, which suggesting that the stock is 30.125% less volatile than S&P 500. In comparison Syndax Pharmaceuticals has a beta of 0.900, suggesting its less volatile than the S&P 500 by 10.021%.

  • Which is a Better Dividend Stock INCY or SNDX?

    Incyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Syndax Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Incyte pays -- of its earnings as a dividend. Syndax Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios INCY or SNDX?

    Incyte quarterly revenues are $1.2B, which are larger than Syndax Pharmaceuticals quarterly revenues of $12.5M. Incyte's net income of $201.2M is higher than Syndax Pharmaceuticals's net income of -$84.1M. Notably, Incyte's price-to-earnings ratio is 267.15x while Syndax Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte is 3.61x versus -- for Syndax Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    INCY
    Incyte
    3.61x 267.15x $1.2B $201.2M
    SNDX
    Syndax Pharmaceuticals
    -- -- $12.5M -$84.1M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Did Walmart Stock Fall?
Why Did Walmart Stock Fall?

Walmart (NYSE:WMT) tumbled in spite of strong Q4 results that…

Is Cadence Stock a Buy, Sell or Hold?
Is Cadence Stock a Buy, Sell or Hold?

Cadence Design Systems (NASDAQ:CDNS) has seen its stock move sharply…

Is PFE the Best Dividend Play in Its Industry?
Is PFE the Best Dividend Play in Its Industry?

By their inherent nature, established pharma companies face a demand…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 40x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Sell
48
Is MSFT Stock a Buy?

Market Cap: $3T
P/E Ratio: 35x

Alerts

Sell
2
GLOB alert for Feb 22

Globant SA [GLOB] is down 27.81% over the past day.

Sell
42
CELH alert for Feb 22

Celsius Holdings [CELH] is up 27.77% over the past day.

Buy
60
HIMS alert for Feb 22

Hims & Hers Health [HIMS] is down 25.64% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock